ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

Core Insights - ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on developing novel therapies for cancer treatment and improving patient survival [2] Group 1: Company Overview - ALX Oncology's lead therapeutic candidate, evorpacept, shows promise as a foundational therapy for future immuno-oncology treatments and is currently undergoing multiple clinical trials across various cancer indications [2] - The second pipeline candidate, ALX2004, is an innovative EGFR-targeted antibody-drug conjugate with a unique mechanism of action, expected to enter Phase 1 trials in mid-2025 [2] Group 2: Upcoming Events - Management will participate in the Jefferies 2025 Global Healthcare Conference, scheduled for June 5, 2025, at 1:25 PM ET in New York, NY [1] - A live webcast of the event will be available on ALX Oncology's website, with a replay accessible for up to 90 days post-event [1]